At meeting held on 12 February 2021
The Board of Glenmark Pharmaceuticals at its meeting held on 12 February 2021 has approved opportunistic tenders or buybacks of any part of its Singapore listed foreign currency convertible bonds, being, its U.S.$200 million (as on date outstanding U.S.$ 113.5 million) 2 per cent resettable onward starting equity linked securities due 28 June 2022 issued in 2016 (FCC Bonds) by the Company (Bond Repurchase"), based on market opportunities and conditions from time to time.Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
